Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nikolai C Brun

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Stroke|January 20, 2009
Can a subset of intracerebral hemorrhage patients benefit from hemostatic therapy with recombinant activated factor VII?Stephan A Mayer, Stephen M Davis, Brett E Skolnick, et al.
Stroke|February 10, 2007
Determinants of intracerebral hemorrhage growth: an exploratory analysisJoseph P Broderick, Michael N Diringer, Michael D Hill, et al.
Cerebrovascular Diseases (Basel, Switzerland)|July 17, 2007
Impact of recombinant activated factor VII on health-related quality of life after intracerebral hemorrhageMichael N Diringer, Jean-Marc Ferran, Joseph Broderick, et al.
The British Journal of Dermatology|September 12, 2023
Izokibep for the treatment of moderate-to-severe plaque psoriasis: a phase II, randomized, placebo-controlled, double-blind, dose-finding multicentre study including long-term treatmentSascha Gerdes, Petra Staubach, Thomas Dirschka, et al.
Clinical Epidemiology|August 28, 2020
Existing Data Sources in Clinical Epidemiology: The Danish COVID-19 CohortAnton Pottegård, Kasper Bruun Kristensen, Mette Reilev, et al.
Annals of the Rheumatic Diseases|June 2, 2025
Efficacy and safety of izokibep in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 studyPeter C Taylor, Philip J Mease, Kurt de Vlam, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Stroke|January 20, 2009
Can a subset of intracerebral hemorrhage patients benefit from hemostatic therapy with recombinant activated factor VII?Stephan A Mayer, Stephen M Davis, Brett E Skolnick, et al.
Stroke|February 10, 2007
Determinants of intracerebral hemorrhage growth: an exploratory analysisJoseph P Broderick, Michael N Diringer, Michael D Hill, et al.
Cerebrovascular Diseases (Basel, Switzerland)|July 17, 2007
Impact of recombinant activated factor VII on health-related quality of life after intracerebral hemorrhageMichael N Diringer, Jean-Marc Ferran, Joseph Broderick, et al.
The British Journal of Dermatology|September 12, 2023
Izokibep for the treatment of moderate-to-severe plaque psoriasis: a phase II, randomized, placebo-controlled, double-blind, dose-finding multicentre study including long-term treatmentSascha Gerdes, Petra Staubach, Thomas Dirschka, et al.
Clinical Epidemiology|August 28, 2020
Existing Data Sources in Clinical Epidemiology: The Danish COVID-19 CohortAnton Pottegård, Kasper Bruun Kristensen, Mette Reilev, et al.
Annals of the Rheumatic Diseases|June 2, 2025
Efficacy and safety of izokibep in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 studyPeter C Taylor, Philip J Mease, Kurt de Vlam, et al.
Pageof 2